FDA OKs RapidAI’s Pulmonary Embolism Triage, Notification Tool

Neurovascular and vascular artificial intelligence (AI)-enhanced clinical decision support and workflow firm RapidAI has earned U.S. Food and Drug Administration (FDA) 510(k) clearance for its Rapid PE triage & notification product to quickly identify and communicate suspected central pulmonary embolism (PE).
 
New research demonstrates a rise in death rates for PE over the past year, with the largest increase among those under 65. Further, a third of these patients will have reoccurrence within 10 years. A tool like Rapid PE can help more efficiently coordinate care, make timely and accurate diagnoses, and send PE patients to treatment faster.
 
“Building on our expertise in stroke, we’re confident this technology will help modernize PE care and meaningfully improve patient outcomes,” Karim Karti, CEO of RapidAI told the press. “Our goal is to build solutions that address the specific challenges associated with treating various conditions, as well as the communication and workflow issues faced by hospitals globally. From stroke to aneurysm to PE, we’re proud of how much RapidAI has grown and are excited to continue to redefine the patient care journey.”
 
Rapid PE triage & notification, together with RapidAI’s Rapid Workflow for PE, can automatically identify suspected PE and send physician a real-time notification for faster triage and care team alignment.
 
“I’m excited to see first-hand how artificial intelligence will transform the way we triage and manage PE, a historically complicated process involving a diverse care team,” said Dr. Jimmy Kerrigan, an Interventional Cardiologist at Ascension St. Thomas Heart. “After seeing what RapidAI technology has done for stroke, I’m optimistic about its potential to optimize our care for patients and to hopefully improve patient outcomes.”